Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415018 · ClinicalTrials.gov registry record · NA
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
A NA study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07415018: Recruiting NA study, sponsored by M.D. Anderson Cancer Center.
NCT07415018 is a NA study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07415018, a NA study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Interventions
- PROCEDURE MRI Scan
- DRUG Gadavist
- DRUG VUEWAY
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2029-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07415018
The ClinicalTrials.gov registry entry for NCT07415018 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MRI Scan is the first listed.
NCT07415018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07415018 about?
NCT07415018 is a clinical study titled "Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease". To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
What is the current status of trial NCT07415018?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-06-10. Estimated completion is 2029-07-31.
What interventions are being tested in trial NCT07415018?
The interventions under investigation include: MRI Scan (PROCEDURE), Gadavist (DRUG), VUEWAY (DRUG).
Who is sponsoring clinical trial NCT07415018?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.